Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diplomat, the nation's largest independent specialty pharmacy, has been selected as a provider of Zydelig tablets. Zydelig was approved by the U.S. Food and Drug Administration on July 23, 2014 for the treatment of three B-cell blood cancers.
Subscribe to our email newsletter
Zydelig was approved by the U.S. Food and Drug Administration on July 23, 2014 for the treatment of three B-cell blood cancers.
"We are pleased to partner with Gilead and be included in the limited panel of distribution for Zydelig," said Gary Kadlec, R.Ph, President of Diplomat. "Our expertise in working with limited-distribution drugs along with our comprehensive patient care programs provides the support needed to improve patient compliance, adherence and outcomes."
Zydelig is indicated for the treatment of relapsed follicular B-Cell non-Hodgkin lymphoma (FL), small lymphocytic lymphoma, and in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL).
Over 200,000 patients in the U.S. are living with FL, SLL or CLL which are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infection and bone marrow failure.
Diplomat’s high-touch approach to patient care achieved a 99% patient satisfaction rating in 2013. The specialty pharmacy’s care programs include timely prescription delivery, side-effect management support and 24 hour access to patient care coordinators, nurses and pharmacists.